Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease?

Naunyn Schmiedebergs Arch Pharmacol. 2016 Nov;389(11):1139-1141. doi: 10.1007/s00210-016-1289-4. Epub 2016 Aug 24.

Authors

Michael Wagner¹, Hind Mehel², Rodolphe Fischmeister², Ali El-Armouche³

Affiliations

¹ Institut für Pharmakologie und Toxikologie, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
² INSERM UMR-S 1180, Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.
³ Institut für Pharmakologie und Toxikologie, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. Ali.El-Armouche@tu-dresden.de.

PMID: 27553701
DOI: 10.1007/s00210-016-1289-4

No abstract available

Publication types

Editorial

MeSH terms

Animals
Cyclic Nucleotide Phosphodiesterases, Type 2 / isolation & purification
Cyclic Nucleotide Phosphodiesterases, Type 2 / metabolism*
Heart / innervation*
Heart Failure / enzymology*
Heart Failure / physiopathology
Humans
Myocardium / enzymology*
Norepinephrine / metabolism*
Prognosis
Receptors, Adrenergic, beta / metabolism*
Signal Transduction
Sympathetic Nervous System / metabolism*
Sympathetic Nervous System / physiopathology

Substances

Receptors, Adrenergic, beta
Cyclic Nucleotide Phosphodiesterases, Type 2
Norepinephrine